Anti-CD20 [1F5]

Absolute Antibody

Anti-CD20 [1F5]

7

This antibody is specific for CD20, which is expressed by normal and malignant B cells.

This antibody, either alone or in combination with T cell derived factors, induces B cell proliferation via CD20 cross-linking (Clark et al, 1985).When administered to patients with refractory malignant B cell lymphomas, this antibody depletes circulating and lymph node tumour cells, with minimal toxicity (Press et al, 1987). A murine/human chimeric IgG1 construct of this antibody has been shown to lyse Burkitts lymphoma (5RAJI) cells (Stockmeyer et al, 2000), while IgG1 and IgA2 isotypes of this antibody have been shown to kill B cells in vitro and in deplete B cells in vivo (Lohse et al, 2018). The humanized version of this antibody can be provided upon request.

Other Application

stimulatory; therapeutic; depleting

Research Use Only

Monoclonal

1F5

MS4A1

membrane spanning 4-domains A1

B1; B-lymphocyte antigen CD20; B-lymphocyte cell-surface antigen B1; Bp35; CD20; CD20 antigen; CD20 receptor; CVID5; FMC7; LEU-16; leukocyte surface antigen Leu-16; membrane-spanning 4-domains, subfamily A, member 1; S7

Mouse

IgG2a

B-lymphocyte antigen CD20

Human

Human

This antibody was raised by hyperimmunising BALB/c mice with the Raji Burkett's lymphoma line and the NALM-6 pre B leukaemia line.

-20°C,2°C to 8°C

12352203